Evidence mapPaperPMID 41378166Full record

ArticleFrontiers in science2025

Precision cardiovascular medicine: shifting the innovation paradigm.

Masanori Aikawa, Abhijeet R Sonawane, Sarvesh Chelvanambi, Takaharu Asano, Arda Halu, Joan T Matamalas, Sasha A Singh, Shizuka Uchida, Elena Aikawa, Alex Arenas and 7 more

Abstract read
In one paragraph

Article in Frontiers in science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Masanori AikawaCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Abhijeet R SonawaneCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Sarvesh ChelvanambiCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Takaharu AsanoCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Arda HaluChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Joan T MatamalasCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Sasha A SinghCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Shizuka UchidaCenter for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
Elena AikawaCenter for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Alex ArenasDepartment of Computer Engineering and Mathematics (DEIM), Rovira I Virgili University (URV), Tarragona, Spain.
Jean-Luc BalligandInstitute of Experimental and Clinical Research, Pole of Pharmacology and Therapeutic, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium.
Chiara GiannarelliNYU Cardiovascular Research Center, Division of Cardiology, Department of Medicine, Department of Pathology, New York University Grossman School of Medicine, New York, NY, United States.
Calum A MacRaeDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Neil V MorganDepartment of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom.
Cécile OuryLaboratory of Cardiology, GIGA-Cardiovascular Sciences, University of Liège, Liège, Belgium.
Hendrik Tevaearai StahelBern University Hospital, University of Bern, Bern, Switzerland.
Joseph LoscalzoDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

Funding

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository CoreOT2HL161847 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 to 2025
$481.6M
L-2-Hydroxyglutarate and Metabolic Remodeling in HypoxiaR01HL155107 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · 2022 to 2025
$2.7M
Nef in impaired efferocytosis: a novel mechanism for vascular disease in HIVR01HL174066 · BRIGHAM AND WOMEN'S HOSPITAL · 2025 to 2025
$740k
Branched-chain Keto-acids and Aerobic Glycolysis in Vascular Smooth Muscle CellsR01HL166137 · BRIGHAM AND WOMEN'S HOSPITAL · 2025 to 2025
$696k
American Heart Association-American Stroke Association 957729NHLBI NIH HHS K25 HL150336NHLBI NIH HHS OT2 HL161847NHLBI NIH HHS R01 HL126901NHLBI NIH HHS R01 HL136431NHLBI NIH HHS R01 HL141917NHLBI NIH HHS R01 HL147095NHLBI NIH HHS R01 HL149302NHLBI NIH HHS R01 HL155107NHLBI NIH HHS R01 HL166137NHLBI NIH HHS R01 HL174066
6 · The paper itself

Abstract

Despite the development of potent drugs for modifiable risk factors and advances in mechanistic biomedical research, cardiovascular diseases (CVDs) collectively remain the leading cause of death globally, indicating a need for new, more effective therapies. A foundational challenge is the multilevel heterogeneity that characterizes CVDs-from their complex pathobiological mechanisms at the molecular and cellular levels, to their clinical presentations and therapeutic responses at the individual and population levels. This variability arises from individuals' unique genomic and exposomic characteristics, underscoring the need for precision approaches. Other key challenges include the long navigation times, high costs, and low success rates for drug development, often compounded by the poor "druggability" of new targets. In this article, we explore how these challenges have inspired novel technologies that offer promise in improving health outcomes globally through an integrative precision medicine approach. Key to this transformation is the use of systems biology and network medicine, whereby the application of artificial intelligence to "big data", ranging from clinical information to unbiased multiomics (e.g., genomics, transcriptomics, proteomics, and metabolomics) can elucidate disease mechanisms, yield novel biomarkers for disease progression, and identify potential drug targets. In parallel, new computational approaches are helping translate these discoveries into novel therapies and overcome druggability barriers. The transition to a precision-based research and innovation paradigm in cardiovascular medicine will require greater interdisciplinary collaboration, data science implementation at every stage, and new partnerships between academia and industry. Global policy leadership is also essential to implement suitable models of research funding and organization, data infrastructures and policies, medicines regulations, and patient access policies promoting equity.

Indexed as

artificial intelligencecardiologycardiovascular diseaseheterogeneitynetwork medicineprecision medicinesystems biology

Identifiers

PMID41378166
PMCPMC12687475

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.